• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the March 10-11, 2010 Joint Meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Committee

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance.

FDA

Disclaimer

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Information (PDF - 6.87MB)

Addendum to the FDA Briefing Information (PDF - 147KB)

Errata to the FDA Briefing Information (PDF - 212KB)

***************

 

AstraZeneca

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

 

AstraZeneca Briefing Information (PDF - 422KB)

***************

 

GlaxoSmithKline

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

GlaxoSmithKline Briefing Information (PDF - 387KB)

***************

 

Novartis

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Novartis Briefing Information (PDF - 687KB)

Errata to the Novartis Briefing Information (PDF - 17.1KB)